Emerging drugs for osteoarthritis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Osteoarthritis (OA), the most prevalent form of joint disease, affects as much as 13% of the world's population. In the USA, it is the leading cause of disability in people over age 65 and is characterized by progressive cartilage loss, bone remodeling, osteophyte formation and synovial inflammation with resultant joint pain and disability. There are no treatments marketed for structural disease modification; current treatments mainly target symptoms, with > 75% of patients reporting need for additional symptomatic treatment. AREAS COVERED: Drugs in later development (Phase II - III) for OA pain and joint structural degeneration are reviewed. Topics that are not covered in this article are procedural-based (e.g., arthrocentesis, physical therapy), behavioral-based (e.g., weight loss, pain coping techniques) or device-based (e.g., knee braces, surgical implants) treatments. EXPERT OPINION: More in-depth understanding of the pathophysiology of the disease, as well as elucidation of the link between clinical symptomatology and structural changes in the joint will likely lead to the development of novel target classes with promising efficacy in the future. Efficacy notwithstanding, there remain significant hurdles to overcome in clinical development of these therapeutics, inherent in the progression pattern of the disease as well as challenges with readouts for both pain and structure modification trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, W., Moskowitz, R. W., Nuki, G., Abramson, S., Altman, R. D., Arden, N., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2008) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.12.013 · Cited by 2,796
Self-citationNeurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298 · cited 3×
“One mechanism may involve formation of a signaling complex of TrkA, PLCg and TRPV1 that increases TRPV1 activity in response to NGF [40].”
BackgroundOsteoarthritis — an untreatable disease?
Wieland, H. A., Michaelis, M., Kirschbaum, B. J., & Rudolphi, K. A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1693 · Cited by 585
The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism
Naot, D., & Cornish, J. (2008) · Bone · doi:10.1016/j.bone.2008.07.003 · Cited by 182
Sondergaard, B. C., Wulf, H., Henriksen, K., Schaller, S., Oestergaard, S., Qvist, P., Tankó, L. B., Bagger, Y. Z., Christiansen, C., & Karsdal, M. A. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.01.014 · Cited by 88
Cited by
The individual and socioeconomic impact of osteoarthritis
Hunter, D. J., Schofield, D., & Callander, E. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.44 · Cited by 1,238
Self-citationGoldring, S. R., & Goldring, M. B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.148 · Cited by 896
Hiligsmann, M., Cooper, C., Arden, N., Boers, M., Branco, J. C., Luisa Brandi, M., Bruyère, O., Guillemin, F., Hochberg, M. C., Hunter, D. J., et al. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.07.003 · Cited by 327
Self-citationCartilage-targeting drug delivery: can electrostatic interactions help?
Bajpayee, A. G., & Grodzinsky, A. J. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.210 · Cited by 325
Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA
Lotz, M. K., & Caramés, B. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.109 · Cited by 314
Metadata
- Authors
- Matthews, G. L., & Hunter, D. J.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa Healthcare
- Published
- 2011-05-04
- Volume
- 16
- Issue
- 3
- Pages
- 479-491
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2105559013
- Cited by
- 98
- References
- 5
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging drugs for osteoarthritis. https://app.cochat.ai/papers/10.1517/14728214.2011.576670
- The paper
- Matthews, G. L., & Hunter, D. J. (2011). Emerging drugs for osteoarthritis. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.2011.576670
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.